The company recently revamped its distribution policy for the domestic market, which we believe would aid the company to achieve higher growth from the domestic market, going ahead. Revenue from India was up 35% during Q3FY20, largely driven by a late Kharif and better Rabi season. Apart from this, new product launches have also helped higher growth during the quarter. Going ahead, the management expects to introduce two new molecules every year along with more focus towards Rabi crop portfolio, diversifying the revenue stream, to a certain extent in the years to come....